Abstract
Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Current Molecular Medicine
Title:Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Volume: 15 Issue: 10
Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti
Affiliation:
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Abstract: Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Export Options
About this article
Cite this article as:
Galuppo M., Mazzon E., Giacoppo S., Bereshchenko O., Bruscoli S., Riccardi C. and Bramanti P., Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?, Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114825
DOI https://dx.doi.org/10.2174/1566524016666151123114825 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Mitochondria-Targeted Drugs
Current Molecular Pharmacology Gene Therapy-Mediated Modulation of Immune Processes in the Central Nervous System
Current Pharmaceutical Design Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods
Current Drug Discovery Technologies The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer’s Disease and Other Inflammation-related Pathologies
Current Alzheimer Research Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Presentation of Lipid Antigens by CD1 Glycoproteins
Current Pharmaceutical Design Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry